Soumettre la recherche
Mettre en ligne
Iv To Po Pp[1]
•
Télécharger en tant que PPT, PDF
•
3 j'aime
•
2,366 vues
Ryan Mills
Suivre
Signaler
Partager
Signaler
Partager
1 sur 13
Télécharger maintenant
Recommandé
In this presentation i have tried to explain in brief about nomograms and their applications, the general approach to individualise doage regimen by using pharmacokinetic data
Nomograms
Nomograms
Dr. Ankit Gaur
Concept of narrow therapeutics drugs, understanding therapeutic drug monitoring definitions, indications
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoring
Dr. Ramesh Bhandari
Basic information on Population pharmacokinetics, understanding bayesian theory, analysis of population pharmacokinetic data
Population pharmacokinetics
Population pharmacokinetics
Dr. Ramesh Bhandari
Gentamicin. Therapeutic drug monitoring.
Gentamicin tdm
Gentamicin tdm
Zeeshan Naseer
Basic information on Pharmacokinetic and pharmacodynamic correlation, Models used in pharmacodynamic
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
Dr. Ramesh Bhandari
It is for clinical situation.
Application of Pharmacokinetics
Application of Pharmacokinetics
AAFahim1
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
pavithra vinayak
TDM
Therapeutic drug monitoring
Therapeutic drug monitoring
Heba Abd Allatif
Recommandé
In this presentation i have tried to explain in brief about nomograms and their applications, the general approach to individualise doage regimen by using pharmacokinetic data
Nomograms
Nomograms
Dr. Ankit Gaur
Concept of narrow therapeutics drugs, understanding therapeutic drug monitoring definitions, indications
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoring
Dr. Ramesh Bhandari
Basic information on Population pharmacokinetics, understanding bayesian theory, analysis of population pharmacokinetic data
Population pharmacokinetics
Population pharmacokinetics
Dr. Ramesh Bhandari
Gentamicin. Therapeutic drug monitoring.
Gentamicin tdm
Gentamicin tdm
Zeeshan Naseer
Basic information on Pharmacokinetic and pharmacodynamic correlation, Models used in pharmacodynamic
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
Dr. Ramesh Bhandari
It is for clinical situation.
Application of Pharmacokinetics
Application of Pharmacokinetics
AAFahim1
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
pavithra vinayak
TDM
Therapeutic drug monitoring
Therapeutic drug monitoring
Heba Abd Allatif
Basic concepts of Clinical Pharmacokinetics
1. Introduction to clinical pharmacokinetics
1. Introduction to clinical pharmacokinetics
Dr. Ramesh Bhandari
Therapeutic Drug Monitoring
Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring
wadalshigil84
Introduction and process of therapeutic drug monitoring
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Dr. Ramesh Bhandari
This presentation was used for practical class of B. Pharmacy students.
TDM for B Pharm practical-2019
TDM for B Pharm practical-2019
Pravin Prasad
This presentation is intended for MBBS 1st year practical. Feedbacks are welcomed!
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Pravin Prasad
The slides explain in detail regarding TDM
Therapeutic drug monitoring
Therapeutic drug monitoring
Urmila Aswar
A SEMINAR ON APPLICATION OF PHARMACOKINETIC IN NEW DRUGDEVELOPMENT AND DESIGNING OF DOSAGE FORM
App p'kinetic 112070804003
App p'kinetic 112070804003
Patel Parth
Pharm D 5th year CPTDM notes - Indications of TDM
Indications of TDM
Indications of TDM
SwarnaPriyaBasker
introduction of tdm criteria for TDM, drugs For which TDMis commonly used, role of pharmacist in performing and evaluating TDM limitations
Therapeutic drug monitoring
Therapeutic drug monitoring
lavanya nalluri
an emerging tool to asses the efficacy of a potential molecule in a computer based model thus saving time and money
Pharmacometrics
Pharmacometrics
Animesh Mandal
Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Bayesian theory
Bayesian theory
pavithra vinayak
Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens
pavithra vinayak
THERAPEUTIC DRUG MONITORING AND SHORTCOMING IN TANZANIA
Therapeutic drug monitoring and shortcoming in tanzania
Therapeutic drug monitoring and shortcoming in tanzania
Paul Mwasapi
Therapeutic drug monitoring final
Therapeutic drug monitoring final
saiesh_phaldesai
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
pavithra vinayak
Therapeutic drug monitoring
Therapeutic drug monitoring
Naser Tadvi
Introduction to population pharmacokinetics, Bayesian theory, and analysis of population pharmacokinetics data.
Population pharamacokinetics
Population pharamacokinetics
Dr. Ramesh Bhandari
Factors considered during Designing dosage form
Design of Dosage form
Design of Dosage form
Dr. Ramesh Bhandari
Therapeutic Drug Monitoring
Therapeutic drug monitoring
Therapeutic drug monitoring
Dr Sajeena Jose
This presentation describes a pharmacist-led antibiotic streamlining service initiative in hospitals in Beirut, and impact on drug costs, length of stay, and rate of hospital admissions
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
MarielleFares1
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Introduction of the NZ Health IT Plan enables better gout management
Introduction of the NZ Health IT Plan enables better gout management
Health Informatics New Zealand
Contenu connexe
Tendances
Basic concepts of Clinical Pharmacokinetics
1. Introduction to clinical pharmacokinetics
1. Introduction to clinical pharmacokinetics
Dr. Ramesh Bhandari
Therapeutic Drug Monitoring
Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring
wadalshigil84
Introduction and process of therapeutic drug monitoring
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Dr. Ramesh Bhandari
This presentation was used for practical class of B. Pharmacy students.
TDM for B Pharm practical-2019
TDM for B Pharm practical-2019
Pravin Prasad
This presentation is intended for MBBS 1st year practical. Feedbacks are welcomed!
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Pravin Prasad
The slides explain in detail regarding TDM
Therapeutic drug monitoring
Therapeutic drug monitoring
Urmila Aswar
A SEMINAR ON APPLICATION OF PHARMACOKINETIC IN NEW DRUGDEVELOPMENT AND DESIGNING OF DOSAGE FORM
App p'kinetic 112070804003
App p'kinetic 112070804003
Patel Parth
Pharm D 5th year CPTDM notes - Indications of TDM
Indications of TDM
Indications of TDM
SwarnaPriyaBasker
introduction of tdm criteria for TDM, drugs For which TDMis commonly used, role of pharmacist in performing and evaluating TDM limitations
Therapeutic drug monitoring
Therapeutic drug monitoring
lavanya nalluri
an emerging tool to asses the efficacy of a potential molecule in a computer based model thus saving time and money
Pharmacometrics
Pharmacometrics
Animesh Mandal
Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Bayesian theory
Bayesian theory
pavithra vinayak
Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens
pavithra vinayak
THERAPEUTIC DRUG MONITORING AND SHORTCOMING IN TANZANIA
Therapeutic drug monitoring and shortcoming in tanzania
Therapeutic drug monitoring and shortcoming in tanzania
Paul Mwasapi
Therapeutic drug monitoring final
Therapeutic drug monitoring final
saiesh_phaldesai
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
pavithra vinayak
Therapeutic drug monitoring
Therapeutic drug monitoring
Naser Tadvi
Introduction to population pharmacokinetics, Bayesian theory, and analysis of population pharmacokinetics data.
Population pharamacokinetics
Population pharamacokinetics
Dr. Ramesh Bhandari
Factors considered during Designing dosage form
Design of Dosage form
Design of Dosage form
Dr. Ramesh Bhandari
Therapeutic Drug Monitoring
Therapeutic drug monitoring
Therapeutic drug monitoring
Dr Sajeena Jose
Tendances
(20)
1. Introduction to clinical pharmacokinetics
1. Introduction to clinical pharmacokinetics
Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
TDM for B Pharm practical-2019
TDM for B Pharm practical-2019
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Therapeutic drug monitoring
Therapeutic drug monitoring
App p'kinetic 112070804003
App p'kinetic 112070804003
Indications of TDM
Indications of TDM
Therapeutic drug monitoring
Therapeutic drug monitoring
Pharmacometrics
Pharmacometrics
Bayesian theory
Bayesian theory
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
Nomograms and tabulations in design of dosage regimens
Nomograms and tabulations in design of dosage regimens
Therapeutic drug monitoring and shortcoming in tanzania
Therapeutic drug monitoring and shortcoming in tanzania
Therapeutic drug monitoring final
Therapeutic drug monitoring final
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
Therapeutic drug monitoring
Therapeutic drug monitoring
Population pharamacokinetics
Population pharamacokinetics
Design of Dosage form
Design of Dosage form
Therapeutic drug monitoring
Therapeutic drug monitoring
Similaire à Iv To Po Pp[1]
This presentation describes a pharmacist-led antibiotic streamlining service initiative in hospitals in Beirut, and impact on drug costs, length of stay, and rate of hospital admissions
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
MarielleFares1
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Introduction of the NZ Health IT Plan enables better gout management
Introduction of the NZ Health IT Plan enables better gout management
Health Informatics New Zealand
Transforming the Office Management of Heart Failure Using the Chronic Disease...
Transforming the Office Management of Heart Failure Using the Chronic Disease...
MedicineAndHealthUSA
Metrics and Decision-Making for Antibiotic Stewardship in Human Medicine - Dr. Steve Solomon, Centers for Disease Control & Prevention, Currently serves as Director of the Office of Antimicrobial Resistance in the Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, in the Office of Infectious Diseases at CDC., from the 2014 NIAA Symposium on Antibiotics Use and Resistance: Moving Forward Through Shared Stewardship, November 12-14, 2014, Atlanta, Georgia, USA. More presentations at http://www.swinecast.com/2014-niaa-antibiotics-moving-forward-through-shared-stewardship
Dr. Steve Solomon - Metrics and Decision-Making for Antibiotic Stewardship in...
Dr. Steve Solomon - Metrics and Decision-Making for Antibiotic Stewardship in...
John Blue
EVIDENCE- BASED CARE SHEET Authors Hillary Mennella, DNP, ANCC-BC Cinahl Information Systems, Glendale, CA Monica Key, ANP-C, APRN, AOCNP, CCRN Cinahl Information Systems, Glendale, CA Reviewers Debra Balderrama, RN, MSCIS Clinical Informatics Services, Tujunga, CA Alysia Gilreath-Osoff, RN, MSN Cinahl Information Systems, Glendale, CA Nursing Executive Practice Council Glendale Adventist Medical Center, Glendale, CA Editor Diane Pravikoff, RN, PhD, FAAN Cinahl Information Systems, Glendale, CA May 20, 2022 Published by Cinahl Information Systems, a division of EBSCO Information Services. Copyright©2022, Cinahl Information Systems. All rights reserved. No part of this may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the publisher. Cinahl Information Systems accepts no liability for advice or information given herein or errors/omissions in the text. It is merely intended as a general informational overview of the subject for the healthcare professional. Cinahl Information Systems, 1509 Wilson Terrace, Glendale, CA 91206 Case Management: Readmissions What We Know › Readmission is defined as a patient admission to the same or a different hospital within a period of 30 days of discharge(3,4) • In the United States, the estimated 30-day, all-cause, hospital readmission rate was 13.9% in 2016, down from 14.2% in 2010(2) –Readmission rates in 2016 varied by patient insurance status, as follows: - Medicare: 17.1% - Medicaid: 13.4% - Uninsured: 11.8% - Private insurance: 8.6% • Common reasons for readmission include premature discharge, inappropriate treatment, and inadequate patient education, discharge planning, and post-discharge monitoring and management(6) –Hospitals serving a higher population of patients from a lower socioeconomic status often have readmission higher rates than the national average. Patients from a lower socioeconomic status can have difficulty procuring follow-upappointments, food, and medications after discharge › In 2010 the Affordable Care Act (ACA) established the Hospital Readmissions Reduction Program, which provides financial incentives to hospitals to reduce readmissions(3,4) • The program requires a reduction in Medicare and Medicaid reimbursement to applicable hospitals for excess readmissions for acute myocardial infarction (AMI), heart failure (HF), pneumonia, chronic obstructive pulmonary disease (COPD), elective hip and/or total knee replacement, and coronary artery bypass graft (CABG) surgery(3,4) –Readmission reimbursement calculations for individual hospitals are based on national readmission rates for these specific diagnoses and are intended to improve health care for beneficiaries and control unnecessary spending of healthcare dollars. Hospitals with high readmission rates will receive lower payments or may be denied payment(3,11 ...
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
BetseyCalderon89
Do we need regional in ERAS?
ERAS and regional anesthesia at PGA 2015
ERAS and regional anesthesia at PGA 2015
Colin McCartney
Poster-v9 (Steven Asbill, TOC)
Poster-v9 (Steven Asbill, TOC)
Min Song, PharmD, BCPS
Presentation to the Ohio State Society of Medical Assistant's annual convention about the Patient Centered Medical Home and the role of the medical assistant
The Healthcare Team as the Healthcare Provider: A Different View of the Patie...
The Healthcare Team as the Healthcare Provider: A Different View of the Patie...
guesta14581
Prevelance of SUP overuse in Alexandria hospitals and determination of factors influencing prescribing behavior among physicians
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)
Neveen Karima
. Treatment of acute event: An initial step in the CV care continuum occurs when treatments are given to address the acute CVD event at hand. For an acute coronary syndrome, prompt provision of antiplatelet therapy, thrombolytic therapy, percutaneous coronary intervention, or some combination of these is critically important to help patients survive the acute event and to do so with minimal damage to the heart.2. Initiation of Secondary Prevention (SP) therapies: A second step in the care continuum occurs shortly after the acute event has resolved and a longer-term treatment plan is initiated. This long-term plan generally includes lifesaving lifestyle and medical therapies and is ideally started before discharge. In fact, evidence shows that when SP treatments are started in the hospital, patients are more likely to adhere to those treatments in the long term, and are more likely to remain free from recurrent CV events than when those treatments were not started before discharge.
Value of secondary prevention in cardiac rehabilitation
Value of secondary prevention in cardiac rehabilitation
ShagufaAmber
Title: Using Quantitative Data to focus Medical Home Facilitation Interventions in the Massachusetts Patient Centered Medical Home Initiative (MA PCMHI)
American Public Health Association- Annual Meeting 2014 Presentation
American Public Health Association- Annual Meeting 2014 Presentation
scherala
08 Am09 Presentations Kliger
08 Am09 Presentations Kliger
Simon Prince
Todd Berner's presentation on how to define effective and efficient real world trials
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World Trials
Todd Berner MD
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...
Todd Berner MD
Fronzi (Ghc)
Fronzi (Ghc)
TORC
Clinical Audit is a method of confirming the quality of clinical services and identify the need for improvement. A skill hospital administrator should learn and practice.
Clinical audit by Dr A. K. Khandelwal
Clinical audit by Dr A. K. Khandelwal
Dr.Ashok Khandelwal
Genesis Presentation
Genesis Presentation
Hai Duong
Diuretic strategies in patients with acute decompensated
Diuretic strategies in patients with acute decompensated
Warawut Ia
Drs. David M Kaplan and Karen Tu
DFCM Top 5 research studies that will impact clinical practice
DFCM Top 5 research studies that will impact clinical practice
Health Quality Ontario (HQO)
Treatment Track: Inpatient and Outpatient Treatments for Pain and Addiction
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
OPUNITE
Similaire à Iv To Po Pp[1]
(20)
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
Pharmacoeconomic Evaluation of an Antibiotic Streamlining Service
Introduction of the NZ Health IT Plan enables better gout management
Introduction of the NZ Health IT Plan enables better gout management
Transforming the Office Management of Heart Failure Using the Chronic Disease...
Transforming the Office Management of Heart Failure Using the Chronic Disease...
Dr. Steve Solomon - Metrics and Decision-Making for Antibiotic Stewardship in...
Dr. Steve Solomon - Metrics and Decision-Making for Antibiotic Stewardship in...
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
ERAS and regional anesthesia at PGA 2015
ERAS and regional anesthesia at PGA 2015
Poster-v9 (Steven Asbill, TOC)
Poster-v9 (Steven Asbill, TOC)
The Healthcare Team as the Healthcare Provider: A Different View of the Patie...
The Healthcare Team as the Healthcare Provider: A Different View of the Patie...
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)
Value of secondary prevention in cardiac rehabilitation
Value of secondary prevention in cardiac rehabilitation
American Public Health Association- Annual Meeting 2014 Presentation
American Public Health Association- Annual Meeting 2014 Presentation
08 Am09 Presentations Kliger
08 Am09 Presentations Kliger
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World Trials
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...
Fronzi (Ghc)
Fronzi (Ghc)
Clinical audit by Dr A. K. Khandelwal
Clinical audit by Dr A. K. Khandelwal
Genesis Presentation
Genesis Presentation
Diuretic strategies in patients with acute decompensated
Diuretic strategies in patients with acute decompensated
DFCM Top 5 research studies that will impact clinical practice
DFCM Top 5 research studies that will impact clinical practice
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
Iv To Po Pp[1]
1.
RYAN MILLS, PHARM.D
CANDIDATE Pharmacist role in MTM at Charleston Area Medical Center Switching patients Intravenous to oral
2.
3.
4.
5.
6.
7.
8.
9.
Methods
10.
11.
12.
13.
Télécharger maintenant